observed a higher risk of hospitalization or death associated with COVID-19 among patients with immune-mediated inflammatory diseases (IMIDs) treated with methotrexate compared with TNF inhibitors, but notably, patients treated with methotrexate in combination with TNF inhibitors had similar rates of hospitalization or death to those treated with TNF inhibitors alone, and importantly, methotrexate determined COVID-19 outcomes in the combination regimen (41). The gene discussed is TNF; the disease is COVID-19.